Currently viewing the tag: "EPO"
Today BioPorto released its Q1 figures. Nothing much was expected, and nothing much was indeed the outcome. I will, as always, start with focusing on the area(s) that are disappointing. But don’t despair yet – hopefully I’ll end on a lighter note
If we look at the turnover – it was perhaps in accordance with […]
The Reasons for the decision by the EPO, regarding the revokation of the NGAL cutoff-patent are now available at the EPO website, in a document titled: “The Grounds for the decision”
In short – the OD does not find that the invention fulfills article 83 and article 100 (summary on page 11) – […]
Unofficial translation of todays annoncement :
BioPortos NGAL cutoff patent EP1831699, issued in Europe november 2010, is provisionally rejected by the Opposition Division at the European Patent Organisation held in Den Haag (Holland) earlier today . BioPorto and Høiberg (The Patent advisor) finds the ruling erroneous and is therefore immediately appealing the decision; until the appeal […]
On the 28’th of December 2011, EPO issued the patent for Bioporto Diagnostics A/S, on the use of NGAL as a marker for the severity of a trauma…
Remember where you heard it first…. more will follow.
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
